Immune checkpoint inhibitor-associated diabetes mellitus: mechanisms, clinical manifestations, and management strategies
Authors:
Top Cited Papers
Open Access
- 13 January 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1679751
Abstract
Immune checkpoint inhibitor–associated diabetes mellitus (ICI-DM) is a rare but life-threatening endocrine immune-related adverse event characterized by abrupt insulin deficiency and a high incidence of diabetic ketoacidosis (DKA). Unlike classical type 1 diabetes, ICI-DM often develops after only a few treatment cycles, shows a fulminant phenotype with disproportionally modest HbA1c elevation, and is typically irreversible and glucocorticoid-refractory, necessitating permanent insulin therapy. Mechanistically, PD-1/PD-L1 blockade disrupts pancreatic immune tolerance and permits autoreactive CD8 + T-cell–mediated β-cell destruction, with risk amplified by susceptible HLA haplotypes and pre-existing islet autoantibodies (most commonly GAD antibodies). Additional contributors include pancreatic inflammation, cytokine-driven immune activation, incretin axis perturbations (GLP-1/GIP), and β-cell dedifferentiation programs. Clinically, timely recognition requires proactive glucose monitoring, early ketone assessment, and evaluation of C-peptide and pancreatic enzymes, particularly because DKA can occur rapidly after symptom onset. This review synthesizes current evidence on ICI-DM epidemiology, pathogenesis, clinical presentation, and management, and discusses emerging preventive and disease-modifying strategies, including mesenchymal stromal cells and B-cell–targeted approaches, to optimize outcomes in patients receiving immunotherapy.Keywords
This publication has 73 references indexed in Scilit:
- Adverse Events Associated with Immune Checkpoint Inhibitors: Overview of Systematic ReviewsDrugs, 2022
- Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literatureReviews in Endocrine and Metabolic Disorders, 2021
- Advances on immune-related adverse events associated with immune checkpoint inhibitorsFrontiers of Medicine, 2020
- Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapyDiabetology International, 2018
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor RegimensJAMA Oncology, 2018
- Autoimmune diabetes induced by PD-1 inhibitor—retrospective analysis and pathogenesis: a case report and literature reviewCancer Immunology, Immunotherapy, 2017
- PD‐L1 gene polymorphisms and low serum level of PD‐L1 protein are associated to type 1 diabetes in ChileDiabetes/Metabolism Research and Reviews, 2014
- Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in ChildrenJAMA, 2013
- Fulminant type 1 diabetes—an important subtype in East AsiaDiabetes/Metabolism Research and Reviews, 2011
- Forced expression of programmed death-1 gene on T cell decreased the incidence of type 1 diabetesArchives of Pharmacal Research, 2010